Prevalence of unipolar major depression in prostate cancer patients undergoing androgen deprivation therapy: The impact of age, treatment duration and prostate cancer stage.

Introduction: Prostate cancer is the most common malignancy among men. Androgen deprivation therapy (ADT), a common treatment for prostate cancer, may contribute to an increased risk for depression. This study examines the prevalence of unipolar major depression in patients undergoing ADT and potential risk factors.

Evaluation of short term surgical outcomes of radical prostatectomy in the decade following the introduction of minimum volume standards in the Netherlands.

Introduction: A minimum volume standard (MVS) of 20 radical prostatectomies (RPs) per institution per year was implemented in the Netherlands in 2014, and raised to 50 RPs in 2018 and 100 in 2019. This study aimed to evaluate the effects of implementing a MVS on the extent of care centralization and short term surgical outcomes.

Methods: All patients who underwent RP between 2014 and 2022 were identified in the nationwide Netherlands Cancer Registry.

Is It the Load That Breaks You or the Way You Carry It: How Demanding Is Endourology?

Surgical outcomes are dependent on multiple factors. Besides patient-related or procedure-related factors, several surgeon-related factors contribute to surgical outcomes. The Surgery Task Load Index (SURG-TLX) questionnaire helps to assess the impact of several stressors on the perceived demands of surgeons during surgery.

Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.

Background: Current surgical and ablative treatment options for prostate cancer (PCa) may result in a high incidence of (temporary) incontinence, erectile dysfunction and/or bowel damage. These side effects are due to procedure related effects on adjacent structures including blood vessels, bowel, urethra and/or neurovascular bundle. Ablation with irreversible electroporation (IRE) has shown to be effective and safe in destroying PCa cells and also has the potential advantage of sparing surrounding tissue and vital structures, resulting in less impaired functional outcomes and maintaining men's quality of life.

[Using rare disease as a research model].

In Europe, a disease is considered to be rare when its prevalence is less than 5:10,000. With approximately 6000-7000 known rare diseases, 1 out of 20 individuals have such a disease. There is little interest in studying rare diseases because results of such research are only applicable to small groups of people.